Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 7/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2429377 | 0.80 | ESR1 (0.47) | ESR1ESR2MEN1NPC1RAB9A | |
| SCHEMBL4812865 | 0.78 | ESR1 (0.46) | ESR1ESR2MEN1NPC1RAB9A | |
| SCHEMBL8193278 | 0.78 | ESR1 (0.50) | ESR1ESR2NPC1RAB9ADEGS1 | |
| SCHEMBL20133367 | 0.77 | ESR1 (0.44) | ESR1ESR2FFAR1DEGS1 | |
| SCHEMBL17141720 | 0.76 | ESR2 (0.41) | ESR1ESR2 | |
| SCHEMBL6810902 | 0.75 | ESR1 (0.47) | ESR1ESR2MEN1NPC1RAB9A | |
| SCHEMBL20436993 | 0.75 | ESR1 (0.43) | ESR1ESR2NPC1RAB9ADEGS1 | |
| Phosphonic Acid SCHEMBL4259990 | 0.75 | ESR1 (0.40) | ESR1ESR2KMT2AFFAR1DEGS1 | |
| SCHEMBL30283084 | 0.75 | ESR1 (0.51) | ESR1ESR2DEGS1 | |
| SCHEMBL1924446 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090209474-A1 | NOVEL USES FOR DRUGS TARGETING GLUTAMINE SYNTHETASE | NEWTHERA (FR) | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209474-A1 | NOVEL USES FOR DRUGS TARGETING GLUTAMINE SYNTHETASE | GLUL, GLS2, ASNS | ESR1 1062/4885ESR2 1519/4885MEN1 3014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.